| Literature DB >> 32915972 |
Gerwin Huls1, Dana A Chitu2, Thomas Pabst3, Saskia K Klein4, Georg Stussi5, Laimonas Griskevicius6, Peter J M Valk7, Jacqueline Cloos8, Arjan A van de Loosdrecht8, Dimitri Breems9, Danielle van Lammeren-Venema10, Isabelle van Zeventer1, Rinske Boersma11, Mojca Jongen-Lavrencic7, Martin Fehr12, Mels Hoogendoorn13, Markus G Manz14, Maaike Söhne15, Rien van Marwijk Kooy16, Dries Deeren17, Marjolein W M van der Poel18, Marie Cecile Legdeur19, Lidwine Tick20, Yves Chalandon21, Emanuele Ammatuna1, Sabine Blum22, Bob Löwenberg7, Gert J Ossenkoppele8.
Abstract
The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data of Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in unfit (ie, Hematopoietic Cell Transplantation Comorbidity Index ≥3) AML patients and higher risk myelodysplasia patients (HOVON135/SAKK30/15 trial). In total, 144 eligible patients were randomly (1:1) assigned to either 10-day decitabine combined with ibrutinib (560 mg; sequentially given, starting the day after the last dose of decitabine) (n = 72) or to 10-day decitabine (n = 72). The addition of ibrutinib was well tolerated, and the number of adverse events was comparable for both arms. In the decitabine plus ibrutinib arm, 41% reached complete remission/complete remission with incomplete hematologic recovery (CR/CRi), the median overall survival (OS) was 11 months, and 2-year OS was 27%; these findings compared with 50% CR/CRi, median OS of 11.5 months, and 2-year OS of 21% for the decitabine group (not significant). Extensive molecular profiling at diagnosis revealed that patients with STAG2, IDH2, and ASXL1 mutations had significantly lower CR/CRi rates, whereas patients with mutations in TP53 had significantly higher CR/CRi rates. Furthermore, multicolor flow cytometry revealed that after 3 cycles of treatment, 28 (49%) of 57 patients with available bone marrow samples had no measurable residual disease. In this limited number of cases, measurable residual disease revealed no apparent impact on event-free survival and OS. In conclusion, the addition of ibrutinib does not improve the therapeutic efficacy of decitabine. This trial was registered at the Netherlands Trial Register (NL5751 [NTR6017]) and has EudraCT number 2015-002855-85.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32915972 PMCID： PMC7509861 DOI： 10.1182/bloodadvances.2020002846
Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529